Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
J Invest Dermatol
    October 2026
  1. KLEIN K, Johnson L, Rica R, Sarcevic M, et al
    Langerhans cell-targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity.
    J Invest Dermatol. 2026;146:2793-2801.
    >> Share

    September 2026
  2. SUI Y, Oh S, Janknecht R
    DNPH1 exerts context-dependent tumor-promoting and -repressing functions during melanoma development.
    J Invest Dermatol. 2026 Sep 22:S0022-202X(26)03712.
    >> Share

  3. AOYAMA K, Kawashima S, Saeki Y, Kawahara Y, et al
    Blockade for CD276-mediated suppression of tumor-specific cytotoxic T lymphocytes may contribute to achieving durable responses with immune checkpoint inhibitors.
    J Invest Dermatol. 2026;146:2554-2564.
    >> Share

    July 2026
  4. O'HAGAN R, Mehta J, Acciardi A, Rodriguez MT, et al
    Depth-aware melanoma classification and Breslow depth estimation from reflectance confocal microscopy.
    J Invest Dermatol. 2026 Jul 21:S0022-202X(26)02680.
    >> Share

  5. LIM SS, Zhao P, Wong NC, Szeto P, et al
    Evaluation of clonality in lentigo maligna.
    J Invest Dermatol. 2026;146:1955-1965.
    >> Share

    June 2026
  6. GHAHARI N, Zheng L, Kuppanda PM, Chandra SS, et al
    Charting a new melanoma risk factor: Satellite Naevus Prevalence in High-Risk and Population-Based Cohorts.
    J Invest Dermatol. 2026 Jun 29:S0022-202X(26)02660.
    >> Share

  7. KING AD, Fisher DE
    Identifying the drivers of genetic risk in patients with multiple primary melanoma.
    J Invest Dermatol. 2026 Jun 11:S0022-202X(26)01008.
    >> Share

  8. NAZIR ZH, Manci R, Nanda JK, Dusza SW, et al
    Diagnostic performance of electrical impedance spectroscopy in patients with multiple nevi and large acquired nevi.
    J Invest Dermatol. 2026;146:1628-1634.
    >> Share

    May 2026
  9. NARAYANA RVL, Lanier AL, Wajapeyee N, Gupta R, et al
    Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells.
    J Invest Dermatol. 2026 May 30:S0022-202X(26)01033.
    >> Share

  10. SAHU A, Gill M, Hermawan A, Shinde A, et al
    PARP1 as a biomarker for differentiating melanoma from benign melanocytic lesions.
    J Invest Dermatol. 2026 May 12:S0022-202X(26)01198.
    >> Share

  11. JAYASINGHE D, Torrano J, Betz-Stablein B, Janda M, et al
    Nevus clustering on the back associated with in situ melanoma in a Queensland melanoma high-risk cohort.
    J Invest Dermatol. 2026 May 6:S0022-202X(26)01186.
    >> Share

    April 2026
  12. BOOSTANI M, Siegel AP, Eathara A, Kiss N, et al
    Skin imaging techniques for melanoma detection: A scoping review of modalities, clinical viability, and deployment strategies.
    J Invest Dermatol. 2026 Apr 24:S0022-202X(26)00754.
    >> Share

  13. YOULDEN DR, Atkinson V, Pinkham MB, Barbour A, et al
    Second primary invasive cutaneous melanomas in Queensland over 4 decades.
    J Invest Dermatol. 2026 Apr 7:S0022-202X(26)00075.
    >> Share

    March 2026
  14. PONCE MB, Heaton AR, Burkard SK, D'Amato A, et al
    Atovaquone-induced therapeutic rewiring of melanoma metabolism.
    J Invest Dermatol. 2026 Mar 23:S0022-202X(26)00969.
    >> Share

  15. CHEN YH, Liau JY, Tsai JF, Liao YH, et al
    Spatial Lipidomics-based Melanoma Diagnostics by Integration of Mass Spectrometry Imaging and Machine Learning.
    J Invest Dermatol. 2026 Mar 17:S0022-202X(26)00963.
    >> Share

  16. ZHAN Y, Dahabieh MS, Rajakumar A, Dobocan MC, et al
    Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].
    J Invest Dermatol. 2026 Mar 13:S0022-202X(25)03516.
    >> Share

    February 2026
  17. JOHANSSON PA, Palmer JM, Brooks KM, Chan HH, et al
    Genetic architecture of multiple primary cutaneous melanoma in the absence of high-penetrance susceptibility genes.
    J Invest Dermatol. 2026 Feb 26:S0022-202X(26)00134.
    >> Share

  18. KUMAR R, Calderon Alonso AI, Ji Z, Njauw CN, et al
    Differential stability of NRAS and BRAF oncoproteins in melanoma.
    J Invest Dermatol. 2026 Feb 26:S0022-202X(26)00131.
    >> Share

  19. RIZO-POTAU D, Fornies-Marine A, Villanueva-Canas JL, Aguilar M, et al
    Exploring global cfDNA fragmentomics as a biomarker in real-world melanoma patients.
    J Invest Dermatol. 2026 Feb 6:S0022-202X(26)00079.
    >> Share

    December 2025
  20. LARUE L
    E-Cadherin, MITF, and Phenotypic Plasticity in Melanoma: A Crossroads between Cell Adhesion, Differentiation, and Hormonal Regulation.
    J Invest Dermatol. 2025 Dec 19:S0022-202X(25)03623.
    >> Share

    November 2025
  21. RAJA DAVID ISAC EB, Sigurbjornsdottir S, Dilshat R, Cornell RA, et al
    Phenotype switching in melanoma cells: MITF regulates the expression of CDH1 through E-boxes in an intronic region.
    J Invest Dermatol. 2025 Nov 26:S0022-202X(25)03605.
    >> Share

    October 2025
  22. ZHOU XMM, Williams K, Will E, Jimenez-Sanchez D, et al
    PD-L1 negative macrophages associate with poor outcomes and high grade irAE development in melanoma patients receiving anti-PD-1 immunotherapy.
    J Invest Dermatol. 2025 Oct 16:S0022-202X(25)03414.
    >> Share

  23. MIZUNO Y, Umemura M, Nagasako A, Akiyama T, et al
    FAK-Dependent Reprogramming of IFN-gamma Signaling through PYK2 Co-Inhibition Sensitizes Melanoma to Immune Checkpoint Blockade.
    J Invest Dermatol. 2025 Oct 14:S0022-202X(25)03407.
    >> Share

    September 2025
  24. XIE J, Zhao S, Wu D, Ma C, et al
    A Metabolism-Driven Prognostic Model and PSMD14-SP1-GYS1 Axis Reveal Therapeutic Vulnerabilities in Melanoma.
    J Invest Dermatol. 2025 Sep 16:S0022-202X(25)02430.
    >> Share

    August 2025
  25. CHAN AA, Noguti J, Ramirez NM, Navarrete M, et al
    Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence.
    J Invest Dermatol. 2025 Aug 18:S0022-202X(25)02342.
    >> Share

    July 2025
  26. CHHABRA G, Su S, Shirley CA, Thornton J, et al
    A melanoma-specific gene network analysis identifies MZB1 (marginal zone B and B1 cell-specific protein) as a potential tumor promoter.
    J Invest Dermatol. 2025 Jul 30:S0022-202X(25)02310.
    >> Share

  27. VAN DEN HURK K, Lommen K, Coussement L, van den Kerkhof D, et al
    Comprehensive analysis of the melanoma DNA methylome identifies Lymphocyte Antigen 75 (LY75) methylation as an independent marker predicting poor clinical outcome.
    J Invest Dermatol. 2025 Jul 30:S0022-202X(25)02311.
    >> Share

  28. PHILIPP T, Nisa Bengu A, Cliff R, Veronica R, et al
    MILK10k: A hierarchical multimodal imaging learning toolkit for diagnosing pigmented and non-pigmented skin cancer and its simulators.
    J Invest Dermatol. 2025 Jul 21:S0022-202X(25)02270.
    >> Share

  29. NG J, Diehl K, Petrie T, Tobey T, et al
    The Melanoma Toolkit for Early Detection Improves Accuracy but Fails to Improve the Number Needed to Biopsy.
    J Invest Dermatol. 2025 Jul 17:S0022-202X(25)02263.
    >> Share

  30. PUHR R, Ryan EG, Couturier DL, van Akkooi ACJ, et al
    Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs.
    J Invest Dermatol. 2025;145:1569-1579.
    >> Share

    May 2025
  31. KENTLEY J, Kurtansky N, Jain M, Cordova M, et al
    Non-invasive diagnosis of melanoma using machine learning and reflectance confocal microscopy.
    J Invest Dermatol. 2025 May 29:S0022-202X(25)00539.
    >> Share

  32. BURKE OM, Ma F, Huang J, Kirsner RS, et al
    Melanoma Incidence and Survival: A SEER Database Study.
    J Invest Dermatol. 2025 May 27:S0022-202X(25)00527.
    >> Share

  33. PERES J, Damerell V, Chauhan J, Popovic A, et al
    Corrigendum to 'TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, which Prevents Activation of E-Cadherin by MITF' Journal of Investigative Dermatology, Volume 141, Issue 9, September 2021, Pages 2250-2260.
    J Invest Dermatol. 2025 May 21:S0022-202X(24)03018.
    >> Share

  34. POLO-SILVEIRA L, Dusza SW, Kentley J, Marchetti MA, et al
    Cutaneous Melanoma Risk Assessment Among Individuals with a High-Risk Nevus Phenotype.
    J Invest Dermatol. 2025 May 13:S0022-202X(25)00478.
    >> Share

    April 2025
  35. DONG L, Wu N, Cai Z, Yan S, et al
    Tolerogenic monocyte-derived langerhans cells promote melanoma progression and immunotherapy resistance through AhR-COX2 activation.
    J Invest Dermatol. 2025 Apr 9:S0022-202X(25)00404.
    >> Share

  36. SU L, Wang D, Purwin TJ, Ran S, et al
    Selective USP7 inhibition synergizes with MEK1/2 inhibitor to enhance immune responses and potentiate anti-PD-1 therapy in NRAS mutant melanoma.
    J Invest Dermatol. 2025 Apr 7:S0022-202X(25)00384.
    >> Share

  37. XIE J, Ma C, Zhao S, Wu D, et al
    Deubiquitination by USP7 Stabilizes JunD and Activates AIFM2 (FSP1) to Inhibit Ferroptosis in Melanoma.
    J Invest Dermatol. 2025 Apr 3:S0022-202X(25)00381.
    >> Share

    March 2025
  38. HAUGH AM, Fisher DE, Lawrence DP
    Tumor-Infiltrating Lymphocyte Therapy for Melanoma Has Arrived (at Last).
    J Invest Dermatol. 2025 Mar 27:S0022-202X(24)03033.
    >> Share

  39. ZHENG L, Soyer HP, Janda M, Jayasinghe D, et al
    An overview of data analysis approaches and biases in unveiling the impact of COVID 19 on melanoma diagnosis.
    J Invest Dermatol. 2025 Mar 25:S0022-202X(25)00371.
    >> Share

  40. MARGUIER A, Mathiot J, NDao B, Wespiser M, et al
    TIE-2 expressing monocytic myeloid-derived suppressor cells are involved in resistance to anti-PD-1 therapy mediated by angiopoietin 2 in melanoma patients.
    J Invest Dermatol. 2025 Mar 18:S0022-202X(25)00327.
    >> Share

  41. MA K, Shafique N, Tortorello G, Dheer A, et al
    Significance of Prognostic Factors Across Tumor Thicknesses in Melanoma: A National Cohort Study.
    J Invest Dermatol. 2025 Mar 12:S0022-202X(25)00321.
    >> Share

  42. CHANG J, Shin K, Lewis JM, Suh HW, et al
    Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol-Coated Biodegradable Nanoparticles.
    J Invest Dermatol. 2025;145:593-604.
    >> Share

    February 2025
  43. AZIMI A, Bi L, Bonfil A, Teh R, et al
    Integrated analysis of proteomic and dermoscopy imaging data improves non-invasive classification of benign nevi and melanoma.
    J Invest Dermatol. 2025 Feb 13:S0022-202X(25)00102.
    >> Share

  44. WHITESIDE TL
    Transfer of Oncologic Signals from Melanoma Cells to Benign Melanocytes by Circulating Tumor-Derived Extracellular Vesicles.
    J Invest Dermatol. 2025 Feb 7:S0022-202X(25)00025.
    >> Share

  45. WONG ZY, Ou KQ, Wong ZN, Faderani R, et al
    Comment on "Does Sex Matter? Temporal Analyses of Melanoma Trends among Men and Women Suggest Etiologic Heterogeneity.".
    J Invest Dermatol. 2025 Feb 4:S0022-202X(25)00005.
    >> Share

    January 2025
  46. MULLER C, Tschandl P, Rinner C, Kyrgidis A, et al
    The BRAAFF-Annotated Acral Lesions Dataset (BALD): A curated set of dermatoscopic images of acral melanoma and nevi from various sources.
    J Invest Dermatol. 2025 Jan 17:S0022-202X(25)00021.
    >> Share

  47. SHEN A, Arbesman M, Lodha R, Rayman P, et al
    Germline Pathogenic Variant (gPV) Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy.
    J Invest Dermatol. 2025 Jan 13:S0022-202X(25)00004.
    >> Share

  48. MENG Y, Zhou Q, Dian Y, Zeng F, et al
    Ferroptosis: A Targetable Vulnerability for Melanoma Treatment.
    J Invest Dermatol. 2025 Jan 8:S0022-202X(24)03024.
    >> Share

  49. TRIBBLE JT, Brownell I, Cahoon EK, Sargen MR, et al
    A comparative study of Merkel cell carcinoma and melanoma incidence and survival in the United States, 2000-2021.
    J Invest Dermatol. 2025 Jan 6:S0022-202X(25)00001.
    >> Share

    December 2024
  50. LEE KJ, Kao YC, Smit DJ, Betz-Stablein B, et al
    Mitochondrial deletion(4977) abundance in melanoma-adjacent skin.
    J Invest Dermatol. 2024 Dec 24:S0022-202X(24)03026.
    >> Share

  51. THAKKER S, Arbesman J, Klein JC, Sunshine JC, et al
    Three-Dimensional Nuclear Architecture and Genomic Structural Variations in Melanoma.
    J Invest Dermatol. 2024 Dec 24:S0022-202X(24)03032.
    >> Share

  52. USOLTSEV D, Njauw CN, Ji Z, Kumar R, et al
    Analysis of variants induced by combined ex vivo irradiation and in vivo tumorigenesis suggests a role for the ZNF831 p.R1393Q mutation in cutaneous melanoma development.
    J Invest Dermatol. 2024 Dec 13:S0022-202X(24)03015.
    >> Share

  53. HAO J, Xu H, Luo M, Yu W, et al
    Corrigendum to The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy [Journal of Investigative Dermatology, Volume 138, Issue 1, January 2018, Pages 159-170].
    J Invest Dermatol. 2024 Dec 6:S0022-202X(24)02184.
    >> Share

    November 2024
  54. LIU X, Janknecht R, Asadbeigi SN, Perry L, et al
    The influence of melanoma extracellular vesicles on benign melanocytes: a role for PRAME in modulation of the tumor microenvironment.
    J Invest Dermatol. 2024 Nov 26:S0022-202X(24)02959.
    >> Share

  55. TONG X, Burks HE, Ren Z, Koetsier JL, et al
    Crosstalk in Skin: Loss of Desmoglein 1 in Keratinocytes Inhibits BRAF(V600E)-induced Cellular Senescence in Human Melanocytes.
    J Invest Dermatol. 2024 Nov 22:S0022-202X(24)02955.
    >> Share

  56. SEYRAN B, Avila I, Galvan C, Robles G, et al
    Inhibition of pyruvate oxidation diminishes melanoma progression.
    J Invest Dermatol. 2024 Nov 18:S0022-202X(24)02902.
    >> Share

  57. GUTIERREZ-GARCIA C, Robles-Espinoza CD
    MicroRNA Quantification as an Accurate and Cost-Effective Method to Diagnose Acral Melanoma.
    J Invest Dermatol. 2024 Nov 1:S0022-202X(24)02098.
    >> Share

  58. WEI G, Tran MM, Orsillo L, Mirza FN, et al
    A Geospatial Analysis of the Association between Access to Tanning Bed Facilities and Melanoma in the United States New England Region.
    J Invest Dermatol. 2024 Nov 1:S0022-202X(24)02172.
    >> Share

    September 2024
  59. MEANT A, Moussa O, Lebeau B, Goncalves C, et al
    Combined inhibition of MNK signaling and BET proteins reveals TGM2 as a novel vulnerability in melanoma.
    J Invest Dermatol. 2024 Sep 30:S0022-202X(24)02160.
    >> Share

  60. SOLER-SAEZ I, Karz A, Hidalgo MR, Gomez-Cabanes B, et al
    Unveiling common transcriptomic features between melanoma brain metastases and neurodegenerative diseases.
    J Invest Dermatol. 2024 Sep 24:S0022-202X(24)02149.
    >> Share

  61. CHHABRA G, Ahmad N
    Mystery of Melanotransferrin in Melanoma.
    J Invest Dermatol. 2024 Sep 14:S0022-202X(24)01994.
    >> Share

    August 2024
  62. RUTJES C, Mothershaw A, D'Alessandro BM, Primiero CA, et al
    Combining Automated Lesion Risk And Change Assessment Improves Melanoma Detection: A Retrospective Accuracy Study.
    J Invest Dermatol. 2024 Aug 23:S0022-202X(24)02060.
    >> Share

  63. DEACON DC, Stubben C, Marcacci E, Stone CJ, et al
    Classification of Cutaneous Melanoma and Melanocytic Nevi with microRNA Ratios is Preserved in the Acral Melanoma Subtype.
    J Invest Dermatol. 2024 Aug 23:S0022-202X(24)02063.
    >> Share

    July 2024
  64. GAUDEL C, Pisibon C, Soysouvanh F, Giuliano S, et al
    Loss of LYN is frequent in targeted-therapy resistant melanoma cells and favors metastatic properties.
    J Invest Dermatol. 2024 Jul 19:S0022-202X(24)01913.
    >> Share

  65. HASSEL JC, Stanhope S, Greenshields-Watson A, Machiraju D, et al
    Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action.
    J Invest Dermatol. 2024 Jul 15:S0022-202X(24)01886.
    >> Share

  66. LATONI DI, Geller A, Semenov YR, Ji Z, et al
    Geotemporal analysis of melanoma incidence and mortality identifies distinct clusters of trends within the United States between 2001-2019.
    J Invest Dermatol. 2024 Jul 7:S0022-202X(24)01874.
    >> Share

    June 2024
  67. CLAUWAERT V, Verhaeghe E, De Schepper S, Haspeslagh M, et al
    Clinicopathologically Defined Naevus Subtypes and Melanoma Risk.
    J Invest Dermatol. 2024 Jun 26:S0022-202X(24)01868.
    >> Share

  68. JANDOVA J, Wondrak GT
    Melanotransferrin (MELTF, MFI2, CD228) expression attenuates malignant melanoma progression in the A375-Luc2 murine metastasis model and human patients.
    J Invest Dermatol. 2024 Jun 21:S0022-202X(24)01864.
    >> Share

  69. KAO YC, Stark MS
    Challenging the Lymph Node Progression Model of Melanoma.
    J Invest Dermatol. 2024 Jun 20:S0022-202X(24)00385.
    >> Share

  70. OLSEN CM, Pandeya N, Miranda-Filho A, Rosenberg PS, et al
    Does sex matter? Temporal analyses of melanoma trends among men and women suggest etiologic heterogeneity.
    J Invest Dermatol. 2024 Jun 17:S0022-202X(24)01500.
    >> Share

    May 2024
  71. NARANPANAWA N, Jayasinghe D, Sturm RA, Betz-Stablein B, et al
    Automated Detection of Pigmented Iris Freckles using a Deep Neural Network for Cutaneous Melanoma Risk.
    J Invest Dermatol. 2024 May 30:S0022-202X(24)00444.
    >> Share

    April 2024
  72. RANDERSON-MOOR J, Davies J, Harland M, Nsengimana J, et al
    Systemic inflammation, the peripheral blood transcriptome and primary melanoma.
    J Invest Dermatol. 2024 Apr 5:S0022-202X(24)00275.
    >> Share

  73. BEZROOKOVE V, Kianian S, McGeever L, Jones R, et al
    The molecular evolution of melanoma distant metastases.
    J Invest Dermatol. 2024 Apr 4:S0022-202X(24)00271.
    >> Share

    March 2024
  74. MOHAMMED NBB, Lau LS, Souchak J, Qiu S, et al
    Tumor-intrinsic galectin-3 suppresses melanoma metastasis.
    J Invest Dermatol. 2024 Mar 6:S0022-202X(24)00169.
    >> Share

    February 2024
  75. OLSEN CM, Pandeya N, Whiteman DC
    Trends in age at melanoma diagnosis according to thickness and histologic subtype have implications for causality and control.
    J Invest Dermatol. 2024 Feb 21:S0022-202X(24)00116.
    >> Share

  76. ROOKER A, Ouwerkerk W, Bekkenk MW, Luiten RM, et al
    The Risk of Keratinocyte Cancer in Vitiligo and the Potential Mechanisms Involved.
    J Invest Dermatol. 2024;144:234-242.
    >> Share

    January 2024
  77. COLLENNE J, Monnier J, Iguernaissi R, Nawaf M, et al
    Fusion between an algorithm based on the characterization of melanocytic lesions asymmetry with an ensemble of CNN for melanoma detection.
    J Invest Dermatol. 2024 Jan 29:S0022-202X(24)00078.
    >> Share

  78. JEREMIAN R, Lytvyn Y, Fotovati R, Georgakopoulos JR, et al
    Distinct signatures of mitotic age acceleration in cutaneous melanoma and acquired melanocytic nevi.
    J Invest Dermatol. 2024 Jan 28:S0022-202X(24)00083.
    >> Share

  79. NAIMY S, Solberg JBK, Kuczek DE, Lovendorf MB, et al
    Comparative quantitative proteomic analysis of melanoma subtypes, nevus-associated melanoma, and corresponding nevi.
    J Invest Dermatol. 2024 Jan 5:S0022-202X(23)03211.
    >> Share

    November 2023
  80. LEE KJ, Soyer HP, Stark MS
    The Skin Molecular Ecosystem Holds the Key to Nevogenesis and Melanomagenesis.
    J Invest Dermatol. 2023 Nov 1:S0022-202X(23)02918.
    >> Share

    September 2023
  81. LIOPYRIS K, Navarrete-Dechent C, Marchetti MA, Rotemberg V, et al
    Expert agreement on the presence and spatial localization of melanocytic features in dermoscopy.
    J Invest Dermatol. 2023 Sep 7:S0022-202X(23)02577.
    >> Share

  82. HAN JH, Lee S, Ju HJ, Kim M, et al
    Automated Mass Screening for Comorbidities of Vitiligo Using the National Health Insurance Database.
    J Invest Dermatol. 2023;143:1717-1723.
    >> Share

    August 2023
  83. FERRER CC, Marguet T, Vanwonterghem L, Erbek S, et al
    Serum IGF1 is a prognostic marker for resistance to targeted therapies and a predictive marker for anti-IGF1R therapy in melanoma.
    J Invest Dermatol. 2023 Aug 12:S0022-202X(23)02499.
    >> Share

  84. VESELY MD, Kidacki M, Gaule P, Gupta S, et al
    Immune inhibitory molecule PD-1H (VISTA) colocalizes with CD11b myeloid cells in melanoma and is associated with poor outcomes.
    J Invest Dermatol. 2023 Aug 7:S0022-202X(23)02483.
    >> Share

  85. MEHTA PP, Sun M, Betz-Stablein B, Halpern A, et al
    Improving Artificial Intelligence-Based Diagnosis on Pediatric Skin Lesions.
    J Invest Dermatol. 2023;143:1423-1429.
    >> Share

    July 2023
  86. AHMED F, Lim R, Moseley I, Hoang M, et al
    Neighborhood-level Socioeconomic Predictors of Melanoma Thickness, Ulceration, and Metastasis at a Rhode Island Academic Center.
    J Invest Dermatol. 2023 Jul 3:S0022-202X(23)02403.
    >> Share

  87. PHUNG M, Muralidharan V, Rotemberg V, Novoa RA, et al
    Best Practices for Clinical Skin Image Acquisition in Translational Artificial Intelligence Research.
    J Invest Dermatol. 2023;143:1127-1132.
    >> Share

    May 2023
  88. TORCHIA D
    Correspondence concerning PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma.
    J Invest Dermatol. 2023 May 24:S0022-202X(23)02127.
    >> Share

  89. GUO Z, Liu Q, Lan S, Niu N, et al
    Clinicopathological Features and Prognosis of Melanoma in Northeast China: a region-based cohort study of 229 consecutive cases.
    J Invest Dermatol. 2023 May 17:S0022-202X(23)02069.
    >> Share

  90. FERGUSON J, Eleftheriadou V, Nesnas J
    RISK OF MELANOMA AND NON-MELANOMA SKIN CANCER IN PEOPLE WITH VITILIGO: UK POPULATION-BASED COHORT STUDY.
    J Invest Dermatol. 2023 May 3:S0022-202X(23)02047.
    >> Share

  91. KANG Y, Ji Z, Li H, Tsao H, et al
    Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.
    J Invest Dermatol. 2023;143:842-853.
    >> Share

    April 2023
  92. AKTARY Z, Raymond JH, Pouteaux M, Delmas V, et al
    Derivation and Use of Cell Lines from Mouse Models of Melanoma.
    J Invest Dermatol. 2023;143:538-544.
    >> Share

    March 2023
  93. MAROCCHI F, Palluzzi F, Nicoli P, Melixetian M, et al
    Actionable genetic screens unveil targeting of AURKA, MEK and fatty acid metabolism as an alternative therapeutic approach for advanced melanoma.
    J Invest Dermatol. 2023 Mar 30:S0022-202X(23)01952.
    >> Share

  94. EDDY K, Gupta K, Pelletier JC, Isola AL, et al
    A SPONTANEOUS MELANOMA MOUSE MODEL APPLICABLE FOR A LONGITUDINAL CHEMOTHERAPY AND IMMUNOTHERAPY STUDY.
    J Invest Dermatol. 2023 Mar 28:S0022-202X(23)01951.
    >> Share

  95. LEICHNER GS, Schweitzer I, Dror S, Levin L, et al
    Primary melanoma miRNAs trafficking induce lymphangiogenesis.
    J Invest Dermatol. 2023 Mar 17:S0022-202X(23)01836.
    >> Share

  96. CHAGANI S, De Macedo MP, Carapeto F, Wang F, et al
    MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA.
    J Invest Dermatol. 2023 Mar 3:S0022-202X(23)00164.
    >> Share

  97. ERIKSSON I, Vainikka L, Waster P, Ollinger K, et al
    Lysosomal function and intracellular position determine the malignant phenotype in malignant melanoma.
    J Invest Dermatol. 2023 Mar 3:S0022-202X(23)00171.
    >> Share

    February 2023
  98. JOHANSSON PA, Palmer JM, Hamilton HR, Whiteman DC, et al
    Germline Variants in Childhood Cutaneous Melanoma.
    J Invest Dermatol. 2023 Feb 28:S0022-202X(23)00155.
    >> Share

  99. WANG G, Zeng D, Sweren E, Miao Y, et al
    m6A RNA methylation correlates with immune microenvironment and immunotherapy response of melanoma.
    J Invest Dermatol. 2023 Feb 24:S0022-202X(23)00095.
    >> Share

  100. RIBERO S, Lambertini M, Ferracin M, Dika E, et al
    Non-Coding RNA Investigations in Cutaneous Melanoma: a Step forward in Discovering Novel Biomarkers.
    J Invest Dermatol. 2023 Feb 24:S0022-202X(23)00088.
    >> Share

    October 2022
  101. LUU YT, Luo Q, Horner MJ, Shiels M, et al
    Risk of nonkeratinocyte skin cancers in people living with HIV during the era of antiretroviral therapy.
    J Invest Dermatol. 2022 Oct 7. pii: S0022-202X(22)01942.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016